Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies

2016 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    1
    Citations
    NaN
    KQI
    []